PharmaWatch: Updates Impacting the Workers’ Compensation Industry

Pharmacist looks at and holds small box in left hand

Timely clinical updates and thought leadership on new drug and indication approvals, discontinuation and withdrawals, new dosages or formulations of existing products and generics introduced to the market. For questions regarding new updates, please email clinical@myMatrixx.com.

News and Updates

ODG Formulary Changes Planned for March 29

March 26, 2024

Effective March 29, ODG is updating Appendix A (its drug formulary). The planned changes will affect opioids, non-steroidal anti-inflammatory drugs (NSAIDs) and sedative hypnotics.

Learn more

FDA Approves Wegovy for Prevention of Major Cardiovascular Disease in Obese or Overweight Adults
On Friday, March 8, 2024, the FDA approved Wegovy (semaglutide) for a new indication--reduction of risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease who are obese or overweight. Wegovy should be used along with increased physical activity and a reduced calorie diet.

Learn more